Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 225 of 232 entries
View as:

Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy

Phase: N/A Priority: Normal
NCT ID: NCT05553366 Org: User:
Start: 10/03/22 End: 12/15/23 Due: 12/15/24

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Phase: N/A Priority: Normal
NCT ID: NCT01754935 Org: User:
Start: 01/31/13 End: 02/28/14 Due: 02/28/15

A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy

Phase: N/A Priority: Normal
NCT ID: NCT04362761 Org: User:
Start: 05/04/20 End: 12/21/22 Due: 12/21/23

A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations

Phase: N/A Priority: Normal
NCT ID: NCT07010406 Org: User:
Start: 06/02/25 End: 08/27/25 Due: 08/27/26

Trial of AVN-944 in Patients With Advanced Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00273936 Org: User:
Start: 01/31/06 End: - Due: -

A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation

Phase: N/A Priority: Normal
NCT ID: NCT02392234 Org: User:
Start: 03/31/15 End: 02/28/17 Due: 02/28/18

Phase 2b Open-label Study of Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease

Phase: N/A Priority: Normal
NCT ID: NCT06794996 Org: User:
Start: 02/04/25 End: 12/30/26 Due: 12/30/27

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease

Phase: N/A Priority: Normal
NCT ID: NCT05312879 Org: User:
Start: 03/30/22 End: 06/30/26 Due: 06/30/27

Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

Phase: N/A Priority: Normal
NCT ID: NCT03633526 Org: User:
Start: 08/03/18 End: 01/18/19 Due: 01/18/20

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

Phase: N/A Priority: Normal
NCT ID: NCT06619860 Org: User:
Start: 10/18/24 End: 05/30/26 Due: 05/30/27

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older

Phase: N/A Priority: Normal
NCT ID: NCT05153317 Org: User:
Start: 01/17/22 End: 04/30/26 Due: 04/30/27

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

Phase: N/A Priority: Normal
NCT ID: NCT05356195 Org: User:
Start: 05/03/22 End: 05/31/26 Due: 05/31/27

Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment

Phase: N/A Priority: Normal
NCT ID: NCT06529796 Org: User:
Start: 08/02/24 End: 12/20/24 Due: 12/20/25

Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation

Phase: N/A Priority: Normal
NCT ID: NCT01707290 Org: User:
Start: 02/28/13 End: 04/30/16 Due: 04/30/17

Phase 1, QT/QTC Interval Study in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01910415 Org: User:
Start: 06/30/13 End: 03/31/14 Due: 03/31/15

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Phase: N/A Priority: Normal
NCT ID: NCT02797132 Org: User:
Start: 05/31/16 End: 09/30/17 Due: 09/30/18

Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

Phase: N/A Priority: Normal
NCT ID: NCT06747572 Org: User:
Start: 12/19/24 End: 12/31/26 Due: 12/31/27

A Phase 1, First-in-human Study of VX-634

Phase: N/A Priority: Normal
NCT ID: NCT05579431 Org: User:
Start: 10/13/22 End: 11/13/23 Due: 11/13/24

An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

Phase: N/A Priority: Normal
NCT ID: NCT01467505 Org: User:
Start: 02/29/12 End: 04/30/14 Due: 04/30/15

Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function

Phase: N/A Priority: Normal
NCT ID: NCT01685801 Org: User:
Start: 09/30/12 End: 04/30/14 Due: 04/30/15

Safety Study of Ivacaftor in Subjects With Cystic Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT00457821 Org: User:
Start: 05/31/07 End: 08/31/08 Due: 08/31/09

A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

Phase: N/A Priority: Normal
NCT ID: NCT00395577 Org: User:
Start: 11/30/06 End: 07/31/07 Due: 07/31/08

A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT02951195 Org: User:
Start: 11/30/16 End: 01/31/18 Due: 01/31/19

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

Phase: N/A Priority: Normal
NCT ID: NCT06299709 Org: User:
Start: 03/13/24 End: 05/23/24 Due: 05/23/25

A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

Phase: N/A Priority: Normal
NCT ID: NCT05668741 Org: User:
Start: 02/27/23 End: 03/31/25 Due: 03/31/26